|
Randomized, placebo-controlled phase II trial (MAJA): Efficacy results of maintenance vinflunine after cisplatin chemotherapy (CT) in patients with advanced urothelial carcinoma (UC)—SOGUG 2011-02. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Astellas Pharma; Novartis; Pfizer; Pierre Fabre |
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen-Cilag; Novartis; Pfizer; Sanofi |
Research Funding - GlaxoSmithKline (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
Aranzazu Gonzalez del Alba |
Consulting or Advisory Role - Astellas Pharma; Bayer; GlaxoSmithKline; Janssen Oncology; Sanofi |
Travel, Accommodations, Expenses - Astellas Pharma; Janssen Oncology; PFIZER |
|
|
|
Consulting or Advisory Role - GlaxoSmithKline; Novartis; Pfizer |
Speakers' Bureau - GlaxoSmithKline; Novartis; Pfizer |
Travel, Accommodations, Expenses - Pfizer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer; Pfizer |
Speakers' Bureau - Pfizer |
Travel, Accommodations, Expenses - Pfizer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; Genentech; Merck; Novartis; Pfizer; Pierre Fabre |
Research Funding - Millennium (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - MSD Oncology; Pfizer |